Cargando…
PSUN188 Evaluating Response to GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Managed at a Veterans Affairs Hospital
Type 2 diabetes mellitus (T2DM) is a leading cause of morbidity and mortality in people of all ages worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer an innovative and unique advancement in treatment for T2DM by not only benefiting blood glucose control but also potentially impac...
Autores principales: | Davis, Clifton, Samson, Kaeli, Kunwar, Sandeep, Desouza, Cyrus, Shivaswamy, Vijay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624607/ http://dx.doi.org/10.1210/jendso/bvac150.778 |
Ejemplares similares
-
RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors
por: Chichura, Kylie, et al.
Publicado: (2022) -
RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis
por: Kodali, Alimitha M, et al.
Publicado: (2022) -
PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022) -
PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis
por: Park, Jeayoung, et al.
Publicado: (2022) -
PSUN134 Loss of Glp-1r Signaling in the β-Cell Impairs Adaptive Proliferation and Insulin Secretion
por: Olvera, Angela, et al.
Publicado: (2022)